

Study Number: I94043
Test Type: TOX
Route: Dosing in Water
Species/Strain: Mouse/B6C3F1/N

M03: Peripheral Blood Leukocyte Cell Differential
Test Compound: Sodium Metavanadate
CAS Number: 13718-26-8

Date Report Requested: 07/08/2021
Time Report Requested: 14:38:24
Lab: Burleson Research Technologies

Study Number: I94043
Study Gender: Female
PWG Approval Date: See web page for date of PWG Approval
Version: v1.2.7
Stat Version: v2.5.2A

Study Number: I94043

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

Date Report Requested: 07/08/2021

Time Report Requested: 14:38:24

Lab: Burleson Research Technologies

Females: Immunopath

Treatment Groups (ppm)

	0	31.3	62.5	125	250	500	50 mg/kg CPS
Leukocytes (10 ³ /μl)	4.756 ± 0.319 (8) *	5.056 ± 0.389 (7)	6.475 ± 0.536 (8)	5.611 ± 0.763 (8)	6.614 ± 0.641 (8)	6.316 ± 0.917 (5)	1.485 ± 0.220 (8) *
Lymphocytes (10 ³ /μl)	3.964 ± 0.268 (8) **	4.269 ± 0.324 (7)	5.480 ± 0.488 (8)	4.675 ± 0.631 (8)	5.695 ± 0.553 (8) *	5.266 ± 0.692 (5) *	1.308 ± 0.211 (8) *
Neutrophils (10 ³ /μl)	0.554 ± 0.059 (8)	0.539 ± 0.052 (7)	0.686 ± 0.071 (8)	0.601 ± 0.086 (8)	0.589 ± 0.068 (8)	0.754 ± 0.181 (5)	0.121 ± 0.006 (8) *
Monocytes (10 ³ /μl)	0.079 ± 0.006 (8) *	0.089 ± 0.010 (7)	0.100 ± 0.011 (8)	0.100 ± 0.015 (8)	0.113 ± 0.011 (8)	0.106 ± 0.019 (5)	0.010 ± 0.000 (8) *
Eosinophils (10 ³ /μl)	0.091 ± 0.008 (8)	0.086 ± 0.010 (7)	0.100 ± 0.014 (8)	0.118 ± 0.020 (8)	0.106 ± 0.013 (8)	0.116 ± 0.017 (5)	0.019 ± 0.004 (8) *
Basophils (10 ³ /μl)	0.019 ± 0.003 (8)	0.011 ± 0.003 (7)	0.019 ± 0.003 (8)	0.016 ± 0.003 (8)	0.023 ± 0.008 (8)	0.014 ± 0.006 (5)	0.001 ± 0.001 (8) *
Large Unstained Cells (10 ³ /μl)	0.049 ± 0.004 (8)	0.066 ± 0.010 (7)	0.086 ± 0.009 (8) *	0.103 ± 0.036 (8)	0.086 ± 0.026 (8)	0.054 ± 0.013 (5)	0.024 ± 0.003 (8) *
Percent Lymphocytes	83.43 ± 0.90 (8)	84.51 ± 0.39 (7)	84.38 ± 1.27 (8)	83.43 ± 0.70 (8)	86.08 ± 0.77 (8)	84.06 ± 1.18 (5)	86.98 ± 1.35 (8) *
Percent Neutrophils	11.58 ± 0.89 (8)	10.57 ± 0.45 (7)	10.80 ± 1.08 (8)	10.74 ± 0.65 (8)	9.08 ± 0.83 (8)	11.36 ± 1.11 (5)	9.01 ± 0.93 (8) *
Percent Monocytes	1.59 ± 0.09 (8)	1.71 ± 0.12 (7)	1.59 ± 0.16 (8)	1.86 ± 0.18 (8)	1.73 ± 0.09 (8)	1.70 ± 0.17 (5)	0.59 ± 0.05 (8) *
Percent Eosinophils	1.99 ± 0.17 (8)	1.76 ± 0.20 (7)	1.54 ± 0.10 (8)	2.09 ± 0.14 (8)	1.64 ± 0.11 (8)	1.86 ± 0.15 (5)	1.58 ± 0.33 (8)
Percent Basophils	0.38 ± 0.07 (8)	0.21 ± 0.03 (7)	0.29 ± 0.03 (8)	0.25 ± 0.04 (8)	0.31 ± 0.06 (8)	0.22 ± 0.05 (5)	0.18 ± 0.02 (8) *
Percent Large Unstained Cells	1.06 ± 0.08 (8)	1.27 ± 0.14 (7)	1.43 ± 0.19 (8)	1.26 ± 0.10 (7)	1.20 ± 0.25 (8)	0.84 ± 0.09 (5)	1.69 ± 0.14 (8) *

Study Number: I94043

Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

Date Report Requested: 07/08/2021

Time Report Requested: 14:38:24

Lab: Burleson Research Technologies

LEGEND

Data are displayed as mean \pm SEM (N) unless otherwise noted.

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

**** END OF REPORT ****